What does the research say about sex hormone-binding globulin?
Sex hormone-binding globulin (SHBG) is a liver-derived glycoprotein that binds androgens and estrogens with high affinity. Research has focused on its role in conditions such as polycystic ovary syndrome (PCOS), where in
What is sex hormone-binding globulin?
Sex hormone-binding globulin (SHBG) is a glycoprotein synthesised primarily in the liver. It binds testosterone, dihydrotestosterone, and estradiol with high affinity, regulating their bioavailability. The formal name is sex hormone-binding globulin; synonyms include SHBG and testosterone-estradiol-binding globulin (TeBG). It belongs to the class of transport proteins. The evidence block does not provide sequence, formula, or molecular weight identifiers.
The pathway or receptor family centred on in the evidence is the insulin sensitivity and glucose homeostasis pathway, with a focus on dipeptidyl peptidase-4 (DPP-4) inhibition and its potential effects on hepatic SHBG synthesis.
Research Studies
Vildagliptin and metformin in polycystic ovary syndrome: effects on SHBG and hyperandrogenism
A clinical trial (NCT07811011) is evaluating vildagliptin versus metformin in patients with polycystic ovary syndrome (PCOS) [1]. PCOS is a common endocrine and metabolic disorder characterised by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, with insulin resistance playing a central role in its pathophysiology. Hyperinsulinemia can enhance ovarian androgen production and reduce hepatic sex hormone-binding globulin synthesis, thereby aggravating hyperandrogenism and reproductive abnormalities. Vildagliptin, a DPP-4 inhibitor, enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis. Emerging evidence suggests that DPP-4 inhibition may also influence body weight, androgen excess, inflammation, and other parameters [1]. The study is registered but results are not yet available in the evidence block.
SHBG and hepatic steatosis in adolescent girls with PCOS
An observational study (NCT07731373) is investigating whether PCOS contributes to hepatic steatosis in adolescent girls independently of adiposity [2]. The study will enrol 150 girls aged 10–18 years into three groups of 50: girls with PCOS and obesity, age- and BMI-matched girls with obesity but without PCOS, and healthy normal-weight girls. Each participant will undergo anthropometry, clinical and biochemical phenotyping, transient elastography with controlled attenuation parameter, two-dimensional shear wave elastography, and a single venous blood sample [2]. SHBG is not explicitly mentioned in the excerpt, but the study's focus on PCOS and metabolic parameters may include SHBG as a biomarker. The evidence block does not provide results.
SHBG as a marker of insulin resistance in PCOS
The evidence block does not contain studies specifically addressing SHBG as a marker of insulin resistance beyond the context of the vildagliptin trial [1]. The trial description notes that hyperinsulinemia reduces hepatic SHBG synthesis, which is a known mechanism. No further studies are provided.
Animal and in vitro studies on SHBG
The evidence block does not include any animal-only or in vitro studies on SHBG. All cited evidence is from human clinical studies or observational protocols.
SHBG and DPP-4 inhibition: mechanistic insights
The vildagliptin trial [1] suggests that DPP-4 inhibition may influence androgen excess and inflammation, potentially via improvements in insulin sensitivity. However, the evidence block does not provide direct mechanistic data on SHBG regulation by DPP-4 inhibitors. The excerpt states that emerging evidence suggests DPP-4 inhibition may also influence body weight, androgen excess, inflammation, and other factors [1].
SHBG in adolescent PCOS: the COMPASS-pedPCOS study
The COMPASS-pedPCOS study [2] is a mechanistic pilot study evaluating PCOS-associated liver steatosis in adolescent girls. While SHBG is not named in the excerpt, the study's biochemical phenotyping may include SHBG measurement. The study aims to determine whether PCOS contributes to hepatic steatosis independently of adiposity. No results are available in the evidence block.
Comparison of vildagliptin and metformin effects on SHBG
The trial NCT07811011 compares vildagliptin and metformin in PCOS patients [1]. The evidence block does not provide outcome data on SHBG levels. The table below summarises the study design.
| Study | Intervention | Population | Primary outcome |
|---|---|---|---|
| NCT07811011 [1] | Vildagliptin vs metformin | PCOS patients | Not specified in excerpt |
| NCT07731373 [2] | Observational | Adolescent girls (PCOS and obesity, obesity without PCOS, healthy) | Hepatic steatosis |
SHBG and metabolic parameters in PCOS
The evidence block does not provide specific data on SHBG correlations with metabolic parameters. The vildagliptin trial [1] mentions that hyperinsulinemia reduces hepatic SHBG synthesis, but no quantitative results are given.
Future directions for SHBG research
The evidence block does not contain information on future research directions beyond the ongoing studies described [1][2].
If you are reading this for personal health reasons
The materials and information discussed here are for laboratory research purposes only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome — ClinicalTrials.gov
- [2] Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) — ClinicalTrials.gov